Top 10 Global Revenue for Cell and Gene Therapies

2024-06-13

上市批准并购基因疗法细胞疗法免疫疗法

According to the latest statistics, cell and gene therapies are rapidly emerging as a hot topic in the pharmaceutical field due to their unique therapeutic advantages. A recent report has revealed the top 10 best-selling cell and gene therapy products globally in 2023.

At the top of the sales ranking is Yescarta, Gilead's CAR-T cell therapy product, which leads the global CAR-T cell therapy market with sales of $1.498 billion, making it the overall sales champion in the cell and gene therapy field. Closely following are two products from Novartis, Zolgensma and Kymriah, which generated sales of $1.214 billion and $508 million, respectively, ranking second and third.

In addition, several other products that made it to the TOP 10 also performed remarkably well, including Carvykti co-developed by Johnson & Johnson and Legend Biotech, Abecma co-launched by BMS and 2seventy bio, and Tecartus from Kite Pharma. It's worth mentioning that if the two antisense oligonucleotide (ASO) therapies for Duchenne muscular dystrophy, Exondys 51 and Amondys 45, developed by Sarepta Therapeutics, were included in the ranking, their 2023 sales of $540 million and $270 million, respectively, would also place them among the top ten.

Looking at the sales ranking, CAR-T cell therapies occupy half of the market, fully demonstrating their outstanding position in the treatment of malignant hematological cancers. Meanwhile, gene therapies based on viral vectors, such as Zolgensma and Luxturna, have also shown impressive market performance.

Looking forward, with the continuous emergence and launch of more innovative therapies, the cell and gene therapy field will embrace a broader development prospect and unlimited market potential.

Menarini Group, as a leading pharmaceutical company in the Italian industry, has weathered 140 years of storms and emerged as an important force in the European and global pharmaceutical industry, thanks to its deep accumulation and excellent technology in the biopharmaceutical field. As a pharmaceutical giant with unique technology, products, and a huge R&D system, Menarini has always focused on the research and development of drugs for cardiovascular diseases, inflammatory pain, gastrointestinal diseases, oncology, and metabolic diseases.

Headquartered in the historic city of Florence, the company has a team of over 17,700 excellent employees and operates in more than 140 countries around the world, with numerous subsidiaries, distributors, and franchisees. In recent years, Menarini has actively expanded its international business footprint and strengthened and expanded its position in the global market through a series of strategic acquisitions and collaborations.

In the fields of oncology and infectious diseases, Menarini, with its rich product line and innovative technology, has provided many high-quality treatment options for patients worldwide. Take Tagraxofusp as an example, it is the first approved drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the first approved CD123-targeted drug, which has brought unprecedented hope for the clinical treatment of BPDCN patients.

Overall, Menarini, with its 140-year deep accumulation and the spirit of continuous innovation, has achieved remarkable results in the fields of oncology and infectious diseases, and continues to provide patients with better treatment options. At the same time, the company also demonstrates strong competitiveness and broad development prospects in the international market.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构